2023年ESMO大会将于10月20日-24日在西班牙马德里举行，大会涵盖了肿瘤领域的基础研究、转化研究以及最新的临床研究进展，为临床实践、多学科讨论等提供广阔、卓越的学术平台。
近日，ESMO官方已公布除Late-breaking abstracts（LBA）外的所有口头摘要题目及作者信息。【肿瘤资讯】特别整理本次公布的新药研发领域重磅研究（主要包含MO：mini oral；O：oral）标题，以飨读者。
Mini oral session
本专场有3个LBA摘要待确认（TBC）
专场时间：2023年10月23日，16:30-18:00
专场地点：Valencia Auditorium - Hall 10
摘要号：656MO
靶向HER2 ADC SHR-A1811治疗HER2表达/突变的晚期非乳腺实体瘤：全球1期研究结果
The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): results from the global phase 1 study
讲者：姚和瑞（中国广州）
摘要号：657MO
抗体免疫刺激偶联药物（ISAC）BDC-1001在晚期表达HER2实体瘤患者（pts）中的首次人体推荐2期剂量（RP2D）选择和药效学（PD）数据
Recommended phase 2 dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors
讲者：Bob T. Li (New York, United States of America)
摘要号：658MO
靶向HER3 ADC SHR-A2009在晚期实体瘤中的1期研究
Phase 1 study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors
讲者：周清（中国湛江）
摘要号：659MO
9MW2821（一种靶向Nectin-4的抗体药物偶联物）在晚期实体瘤患者中的I/II期研究的初步结果
Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting Nectin-4, in patients with advanced solid tumors
讲者：张剑（中国上海）
摘要号：660MO
靶向B7-H4 ADC SGN-B7H4V在晚期实体瘤患者中的首次人体研究：1期研究的初步结果（SGNB7H4V-001）
First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase 1 study (SGNB7H4V-001)
讲者：Cesar A. Perez (Fort Myers, United States of America)
摘要号：661MO
Belvarafenib联合Cobimetinib对携带BRAF融合或BRAF II/III类突变的转移性实体瘤患者的抗肿瘤活性
Anti-Tumor Activity of Belvarafenib in combination with Cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation
讲者：Tae Won Kim (Seoul, Korea, Republic of)
摘要号：662MO
WEE1抑制剂IMP7068在晚期实体瘤患者中的1期多中心剂量递增和剂量扩展研究
Phase 1, Multi-Center, Dose-escalation and Dose-expansion Study of IMP7068, a WEE1 Inhibitor, in Patients with Advanced Solid Tumors
讲者：Chia-Chi Lin (Taipei City, Taiwan)
Proffered Paper session
本专场有1个LBA摘要待确认（TBC）
专场时间：2023年10月22日
专场地点：Málaga Auditorium - Hall 10
专场主席：Lillian L. Siu (Toronto, Canada) Elena Garralda (Barcelona, Spain)
摘要号：652O
RMC-6236（一种新型RAS-选择性、三复合RAS-MULTI（ON）抑制剂）在KRAS突变型胰腺导管腺癌（PDAC）和非小细胞肺癌（NSCLC）患者中的初步临床活性
Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
讲者：Kathryn C. Arbour (New York, United States of America)
摘要号：653O
Glecirasib（KRAS G12C抑制剂）与JAB-3312（SHP2抑制剂）联合治疗KRAS p.G12C突变实体瘤患者
Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in Patients with KRAS p.G12C mutated solid tumors.
讲者：王洁 (中国北京)
摘要号：654O
曲妥珠单抗（T-DXd）治疗HER2阳性实体瘤患者（pts）的疗效和安全性：国际2期DESTINY-PanTumor01（DPT-01）研究的主要结果
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the international phase 2 DESTINY-PanTumor01 (DPT-01) study
讲者：Bob T. Li (New York, United States of America)
摘要号：655O
Cofetuzumab Pelidotin（一种抗-PTK7抗体药物偶联物）在表达PTK7复发性非小细胞肺癌（rNSCLC）患者中的1b期研究
Phase 1b Study of Cofetuzumab Pelidotin, an Anti-PTK7 Antibody-Drug Conjugate, in Patients with PTK7-Expressing Recurrent Non-Small Cell Lung Cancer (rNSCLC)
讲者：Byoung Chul Cho (Seoul, Korea, Republic of)
排版编辑：肿瘤资讯-云初
苏公网安备32059002004080号
